According to a press release a law firm is currently on behalf of Alpharma, Inc. (NYSE:ALO) shareholders investigating potential Alpharma, Inc. (NYSE:ALO) shareholder claims arising from the proposed acquisition of Alpharma, Inc. by King Pharmaceuticals, Inc.

According to the press release on November 24, 2008 King Pharmaceuticals Inc. and Alpharma, Inc. announced the signing of a definitive merger agreement under which King Pharmaceuticals Inc. will acquire all the outstanding Class A shares of Alpharma, Inc. for $37.00 cash per share. Both companies Boards unanimously approved the transaction. Just two months ago, in September of 2008, the Alpharma board issued a letter to shareholders unanimously recommending that shareholders reject the $37.00 offer, stating that it was financially inadequate and not in the best interest of Alpharmas shareholders, so the investigation.